Wednesday, 4 December 2013

Guangzhou oncologists develop better staging method for colon cancer

Guangzhou oncologists have developed an improved staging method for colon cancer that accurately predicts the risk of disease recurrence and benefit of adjuvant chemotherapy for patients who have had surgery for stage II colon cancer.
Researchers from the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, used expression patterns of multiple microRNAs (miRNAs) combined into a single model to improve postoperative risk stratification and prediction of chemotherapy benefit for these patients.
Using this tool, they were able to classify patients as at high risk or low risk of disease progression. Five year disease-free survival was was 85% for the low-risk group, and 57% for the high-risk group. The six-miRNA-based classifier was an independent prognostic factor for, and had better prognostic value than, clinicopathological risk factors and mismatch repair status.
Patients in the high-risk group were found to have a favourable response to adjuvant chemotherapy The clinicians developed two nomograms which combined the smiRNA-based classifiers and clinicopathological risk factors to predict which patients might benefit from adjuvant chemotherapy after surgery for stage II colon cancer.
“Our six-miRNA-based classifier is a reliable prognostic and predictive tool for disease recurrence in patients with stage II colon cancer, and might be able to predict which patients benefit from adjuvant chemotherapy. It might facilitate patient counselling and individualise management of patients with this disease,” they concluded.
Full study: Lancet Oncology

No comments:

Post a comment

Add a comment